"Antibodies, Monoclonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies produced by a single clone of cells.
| Descriptor ID |
D000911
|
| MeSH Number(s) |
D12.776.124.486.485.114.224 D12.776.124.790.651.114.224 D12.776.377.715.548.114.224
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal".
This graph shows the total number of publications written about "Antibodies, Monoclonal" by people in this website by year, and whether "Antibodies, Monoclonal" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 42 | 107 | 149 |
| 1996 | 43 | 83 | 126 |
| 1997 | 42 | 75 | 117 |
| 1998 | 50 | 77 | 127 |
| 1999 | 56 | 83 | 139 |
| 2000 | 41 | 72 | 113 |
| 2001 | 59 | 80 | 139 |
| 2002 | 69 | 72 | 141 |
| 2003 | 52 | 91 | 143 |
| 2004 | 75 | 67 | 142 |
| 2005 | 96 | 89 | 185 |
| 2006 | 102 | 93 | 195 |
| 2007 | 128 | 89 | 217 |
| 2008 | 104 | 99 | 203 |
| 2009 | 117 | 83 | 200 |
| 2010 | 143 | 97 | 240 |
| 2011 | 130 | 82 | 212 |
| 2012 | 99 | 71 | 170 |
| 2013 | 98 | 48 | 146 |
| 2014 | 108 | 54 | 162 |
| 2015 | 105 | 45 | 150 |
| 2016 | 104 | 63 | 167 |
| 2017 | 126 | 65 | 191 |
| 2018 | 119 | 52 | 171 |
| 2019 | 86 | 51 | 137 |
| 2020 | 80 | 66 | 146 |
| 2021 | 51 | 78 | 129 |
| 2022 | 17 | 96 | 113 |
| 2023 | 16 | 100 | 116 |
| 2024 | 47 | 36 | 83 |
| 2025 | 3 | 3 | 6 |
Below are the most recent publications written about "Antibodies, Monoclonal" by people in Profiles.
-
Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infection. JCI Insight. 2025 Feb 24; 10(4).
-
Evaluation and Real-world Experience of a Neutralization Susceptibility Screening Assay for Broadly Neutralizing Anti-HIV-1 Antibodies. J Infect Dis. 2025 Feb 20; 231(2):424-434.
-
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV. BMC Immunol. 2025 Feb 19; 26(1):8.
-
Viral and Symptom Rebound Following Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled Trial. J Infect Dis. 2025 Feb 04; 231(1):131-136.
-
Anti-Ebola virus mAb 3A6 protects highly viremic animals from fatal outcome via binding GP(1,2) in a position elevated from the virion membrane. Nat Commun. 2025 Feb 03; 16(1):1293.
-
Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study. Blood. 2025 Jan 16; 145(3):300-310.
-
Disrupted callosal connectivity underlies long-lasting sensory-motor deficits in an NMDA receptor antibody encephalitis mouse model. J Clin Invest. 2024 Dec 31; 135(5).
-
Development of Peptide Mimics of the Human Acetylcholine Receptor Main Immunogenic Region for Treating Myasthenia Gravis. Int J Mol Sci. 2024 Dec 30; 26(1).
-
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial. Lancet HIV. 2025 Jan; 12(1):e13-e25.
-
Enhanced Prenatal and Postnatal Development Study in Marmoset Monkeys Following Administration of Felzartamab. Int J Toxicol. 2024 Dec; 43(6):561-578.